We Think Valeant Still Has Over 40% Downside | $VRX

03/15/16 03:17PM EDT

We Think Valeant Still Has Over 40% Downside | $VRX - Ackman cartoon 10.26.2015

Ka-boom ... Shares of Valeant Pharmaceuticals (VRX) were cut in half today after the company cut its 2016 revenue forecast by 12% and said a delay in filing its annual report could pose a debt default risk. Our Healthcare analysts Tom Tobin and Andrew Freedman have been warning about the company's "unsustainable business model" for a while now.

Here's the "VRX | Bear Case $20" note in its entirety:

We Think Valeant Still Has Over 40% Downside | $VRX - valeant

Never fear Valeant shareholders! Wall Street consensus still sees 257% upside from here.

Click to enlarge

We Think Valeant Still Has Over 40% Downside | $VRX - valeant price target

Now, that's obviously ridiculous. But so is the sell side's track record for predicting a VRX price target. Check out the chart below. Keep in mind that Valeant shares currently trade around $35. 

We Think Valeant Still Has Over 40% Downside | $VRX - graph valeant

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.